Sanctuary Advisors LLC Increases Holdings in Hims & Hers Health, Inc. $HIMS

Sanctuary Advisors LLC raised its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 16.8% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 128,116 shares of the company’s stock after buying an additional 18,443 shares during the quarter. Sanctuary Advisors LLC’s holdings in Hims & Hers Health were worth $4,160,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. VIRGINIA RETIREMENT SYSTEMS ET Al increased its stake in shares of Hims & Hers Health by 0.8% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,600 shares of the company’s stock worth $1,452,000 after purchasing an additional 200 shares in the last quarter. Concurrent Investment Advisors LLC boosted its holdings in Hims & Hers Health by 1.8% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 13,984 shares of the company’s stock worth $793,000 after buying an additional 252 shares during the period. Smartleaf Asset Management LLC boosted its holdings in shares of Hims & Hers Health by 44.7% during the 3rd quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock valued at $54,000 after purchasing an additional 283 shares during the last quarter. W.G. Shaheen & Associates DBA Whitney & Co boosted its holdings in shares of Hims & Hers Health by 4.8% during the 3rd quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 7,695 shares of the company’s stock valued at $436,000 after purchasing an additional 350 shares during the last quarter. Finally, BAM Wealth Management LLC boosted its holdings in shares of Hims & Hers Health by 5.6% during the 4th quarter. BAM Wealth Management LLC now owns 7,380 shares of the company’s stock valued at $240,000 after purchasing an additional 393 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on HIMS. JPMorgan Chase & Co. began coverage on shares of Hims & Hers Health in a report on Friday, April 24th. They issued an “overweight” rating and a $35.00 price target for the company. Truist Financial reissued a “hold” rating and issued a $18.00 price objective (down from $37.00) on shares of Hims & Hers Health in a research report on Tuesday, February 24th. Evercore set a $24.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, February 24th. Leerink Partners increased their price objective on shares of Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a research report on Monday, March 16th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a research report on Friday, March 27th. Four investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and a consensus price target of $32.53.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS opened at $27.27 on Friday. The firm has a market cap of $6.22 billion, a PE ratio of 53.47, a price-to-earnings-growth ratio of 2.72 and a beta of 2.32. The firm’s 50 day simple moving average is $21.91 and its 200-day simple moving average is $30.73. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $70.43. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.06. The business had revenue of $617.82 million for the quarter, compared to analyst estimates of $619.48 million. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The company’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same period last year, the company posted $0.11 earnings per share. As a group, equities analysts predict that Hims & Hers Health, Inc. will post 0.56 EPS for the current year.

Insider Activity at Hims & Hers Health

In other news, insider Irene Becklund sold 5,529 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $136,511.01. Following the transaction, the insider directly owned 8,752 shares of the company’s stock, valued at approximately $216,086.88. This trade represents a 38.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Soleil Boughton sold 9,463 shares of the firm’s stock in a transaction that occurred on Monday, April 20th. The stock was sold at an average price of $30.00, for a total transaction of $283,890.00. Following the transaction, the insider directly owned 299,368 shares in the company, valued at approximately $8,981,040. This trade represents a 3.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 204,857 shares of company stock valued at $5,285,706. 13.71% of the stock is owned by insiders.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.